The changing landscape of axillary surgery: which breast cancer patients may still benefit from complete axillary lymph node dissection?

J Surg Oncol. 2012 Sep 1;106(3):254-9. doi: 10.1002/jso.22131. Epub 2011 Oct 27.

Abstract

Background and objectives: Many breast cancer patients undergoing completion axillary lymph node dissection (CALND) for sentinel lymph node (SLN) metastases have no further disease. Predicting patients at high risk of non-sentinel lymph node (NSLN) metastasis may help guide effective utilization of CALND.

Methods: SLN+ breast cancer patients undergoing frozen section (FS) analysis at a single institution (2004-2010) were studied retrospectively. Factors associated with NSLN metastases were identified.

Results: Two-hundred forty SLN+ patients were identified. The incidence of NSLN metastases was 45% in FS(+) patients undergoing CALND, compared to 10% of FS(-) patients following CALND (P < 0.001). Multivariate analysis revealed that FS positivity, tumor size, and the presence of angiolymphatic invasion were significant factors associated with NSLN metastases (all P < 0.05). Further analysis of FS(+) patients revealed that tumor size, ER(-) status, and lymph node metastasis size were also associated with risk of NSLN metastases. An algorithm for the management of the axilla in SLN+ breast cancer patients was devised, based on clinic-pathologic predictors of NSLN metastases.

Conclusion: A SLN+ biopsy by FS predicts the presence of NSLN metastases and, in combination with other factors, may justify immediate CALND. CALND may, however, be avoided in selected low-risk SLN+ patients.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Algorithms
  • Axilla
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / surgery
  • Carcinoma, Ductal, Breast / metabolism
  • Carcinoma, Ductal, Breast / mortality
  • Carcinoma, Ductal, Breast / pathology
  • Carcinoma, Ductal, Breast / surgery
  • Carcinoma, Lobular / metabolism
  • Carcinoma, Lobular / mortality
  • Carcinoma, Lobular / pathology
  • Carcinoma, Lobular / surgery
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Lymph Node Excision*
  • Lymphatic Metastasis
  • Middle Aged
  • Receptor, ErbB-2 / metabolism
  • Retrospective Studies
  • Risk Assessment*

Substances

  • ERBB2 protein, human
  • Receptor, ErbB-2